Healthcare [ 11/13 ] | Medical Devices [ 114/159 ]
NYSE | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 4, 23 | 0.02 Decreased by -83.33% | - |
| Dec 31, 22 | 0.01 Decreased by -36% | - |
| Nov 21, 22 | 0.08 Decreased by -55.56% | - |
| Aug 15, 22 | 0.09 Increased by +190% | - |
| May 13, 22 | 0.12 Increased by +340% | - |
| Mar 31, 22 | 0.02 | - |
| Nov 19, 21 | 0.18 | - |
| Aug 16, 21 | -0.1 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 18.2 M Increased by +13.3% | -21.63 M Decreased by -59.37% | Decreased by -118.85% Decreased by -40.67% |
| Jun 30, 23 | 12.96 M Decreased by -20.25% | -22 M Decreased by -306.96% | Decreased by -169.72% Decreased by -410.27% |
| Mar 31, 23 | 14.07 M Increased by +10.68% | -17.8 M Decreased by -177.32% | Decreased by -126.51% Decreased by -150.55% |
| Dec 31, 22 | 19.18 M - | -12.35 M - | Decreased by -64.37% - |
| Sep 30, 22 | 16.06 M - | -13.57 M - | Decreased by -84.49% - |
| Jun 30, 22 | 16.25 M - | -5.41 M - | Decreased by -33.26% - |
| Mar 31, 22 | 12.71 M - | -6.42 M - | Decreased by -50.49% - |
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.